Immatics (NASDAQ:IMTX) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP lifted its holdings in Immatics (NASDAQ:IMTX - Free Report) by 7.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,417,892 shares of the company's stock after purchasing an additional 736,709 shares during the period. Wellington Management Group LLP owned about 8.73% of Immatics worth $74,071,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of America Corp DE increased its stake in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after purchasing an additional 2,231 shares in the last quarter. Virtus ETF Advisers LLC boosted its holdings in Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after buying an additional 2,479 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in Immatics in the 4th quarter worth about $101,000. Forefront Analytics LLC boosted its holdings in Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock worth $113,000 after buying an additional 4,731 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in Immatics in the 4th quarter worth about $130,000. Hedge funds and other institutional investors own 64.41% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on IMTX shares. Deutsche Bank Aktiengesellschaft started coverage on Immatics in a report on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st. Finally, Wall Street Zen cut Immatics from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Immatics has an average rating of "Moderate Buy" and an average target price of $14.67.

Immatics Stock Up 11.5%

Shares of Immatics stock traded up $0.62 on Monday, hitting $6.01. 1,732,169 shares of the company were exchanged, compared to its average volume of 652,757. The stock has a market capitalization of $730.52 million, a price-to-earnings ratio of -9.11 and a beta of 0.87. The company has a 50-day moving average price of $4.57 and a 200 day moving average price of $5.54. Immatics has a 1-year low of $3.30 and a 1-year high of $13.77.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.04. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The firm had revenue of $20.12 million for the quarter, compared to analysts' expectations of $14.92 million. Research analysts forecast that Immatics will post -0.72 EPS for the current year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.